Industry Prepares For Advent Of SPC Manufacturing Waiver

As the generics and biosimilars industries prepare for the European SPC manufacturing waiver to come into effect on 1 July, Generics Bulletin traces the history of the mechanism from early industry lobbying efforts to its ultimate entry into force.

July
On 1 July The SPC Waiver Regulation Comes Into Effect • Source: Shutterstock

On 1 July, European Regulation 2019/933 enters into force, marking the end of a long journey for the generics and biosimilars industries in its pursuit of a waiver to allow manufacturing for export outside the European Union – as well as stockpiling for day-one launch within the EU – during the term of supplementary protection certificates.

Amending the European SPC Regulation 469/2009, the waiver Regulation is the culmination of more than a decade of lobbying efforts...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Regulation

More from Policy & Regulation

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Policy&Regulation-Free: Article with different widgets

    Emerging CRISPR innovations, shifting regulatory landscapes, and rising partnerships are accelerating a paradigm shift in biotech pipelines

  • Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

    After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.